Analystreport

Allogene Therapeutics Inc. (NASDAQ: ALLO) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock.

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report